Thatthan Suksombooncharoen

Statistics

Publications

Citations

1.6K

H-Index

Active since

2022

Affiliations

Nanjing General Hospital of Nanjing Military Command(Current)

Jiangsu Cancer Hospital

Assistance Publique – Hôpitaux de Paris

The Catholic University of Korea Seoul St. Mary's Hospital

Seoul National University Hospital

Thatthan Suksombooncharoen is an author at Nanjing General Hospital of Nanjing Military Command specializing in oncology, durvalumab therapy, and chemotherapy.

Publications per year

2022–2025

Publications

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · NEJM Evidence · 2022 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +14

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour et al. · The Lancet. Gastroenterology & hepatology · 2024 · 254 citations · Full text

Medicine, Oncology, Pharmacology +11

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · Journal of Clinical Oncology · 2022 · 235 citations

Medicine, Oncology, Pharmacology +17

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · Journal of Hepatology · 2025 · 49 citations

Medicine, Oncology, Pharmacology +7

Plain Language Summary of the TOPAZ-1 Study: Durvalumab and Chemotherapy for Advanced Biliary Tract Cancer

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · Future Oncology · 2023 · 10 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

1–5 of 5